MA33260B1 - 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines - Google Patents

6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines

Info

Publication number
MA33260B1
MA33260B1 MA34332A MA34332A MA33260B1 MA 33260 B1 MA33260 B1 MA 33260B1 MA 34332 A MA34332 A MA 34332A MA 34332 A MA34332 A MA 34332A MA 33260 B1 MA33260 B1 MA 33260B1
Authority
MA
Morocco
Prior art keywords
azabicyclo
hex
phenylpyrimidines
platletary
cerebrovascular
Prior art date
Application number
MA34332A
Other languages
English (en)
Inventor
Eva Caroff
Kurt Hilpert
Francis Hubler
Emmanuel Meyer
Dorte Renneberg
Original Assignee
Actelion Pharmaceuticals Ltd
Saba & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd, Saba & Co filed Critical Actelion Pharmaceuticals Ltd
Publication of MA33260B1 publication Critical patent/MA33260B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION PORTE SUR DES DÉRIVÉS 6-(3-AZABICYCLO[3.1.0]HEX-3-YL)-2-PHÉNYLPYRIMIDINES ET SUR LEUR UTILISATION COMME ANTAGONISTES DU RÉCEPTEUR P2Y12 DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES VASCULAIRES PÉRIPHÉRIQUES, VISCÉRALES, HÉPATIQUES ET VASCULAIRES RÉNALES, CARDIOVASCULAIRES ET CÉRÉBROVASCULAIRES OU D'AFFECTIONS ASSOCIÉES À L'AGRÉGATION PLAQUETTAIRE, DONT LA THROMBOSE CHEZ L'HOMME ET D'AUTRES MAMMIFÈRES.
MA34332A 2009-04-08 2010-04-07 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines MA33260B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2009051486 2009-04-08
PCT/IB2010/051499 WO2010116328A2 (fr) 2009-04-08 2010-04-07 6-(3-azabicyclo[3.1.0]hex-3-yl)-2-phénylpyrimidines

Publications (1)

Publication Number Publication Date
MA33260B1 true MA33260B1 (fr) 2012-05-02

Family

ID=42936647

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34332A MA33260B1 (fr) 2009-04-08 2010-04-07 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines

Country Status (18)

Country Link
US (1) US8288385B2 (fr)
EP (1) EP2417128B1 (fr)
JP (1) JP5536873B2 (fr)
KR (1) KR101694563B1 (fr)
CN (1) CN102369197B (fr)
AU (1) AU2010233378A1 (fr)
BR (1) BRPI1014039A2 (fr)
CA (1) CA2756542C (fr)
CL (1) CL2011002467A1 (fr)
ES (1) ES2567311T3 (fr)
IL (1) IL215517A0 (fr)
MA (1) MA33260B1 (fr)
MX (1) MX2011010200A (fr)
NZ (1) NZ596213A (fr)
RU (1) RU2011144763A (fr)
SG (1) SG175075A1 (fr)
WO (1) WO2010116328A2 (fr)
ZA (1) ZA201108158B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
EP2225253B1 (fr) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Dérivés d'acide phosphonique et leur utilisation en tant qu'antagonistes du récepteur p2y12
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
CA2756654C (fr) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Derives de thiazole et leur utilisation comme antagonistes des recepteurs p2y12
US9662339B2 (en) 2012-03-06 2017-05-30 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production for combination therapy
EP2968737A4 (fr) * 2013-03-15 2016-11-09 Concert Medical Llc Procédé et système permettant l'administration de fluide à un patient et/ou le retrait de fluide d'un patient, de façon contrôlable
SI3397631T1 (sl) * 2015-12-29 2022-01-31 Pfizer Inc. Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
TWI732031B (zh) 2016-08-31 2021-07-01 日商衛材R&D企管股份有限公司 吡唑并[1, 5-a]嘧啶化合物
EP3515924B1 (fr) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Formes cristallines
MA49887A (fr) 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
CN113412260B (zh) 2019-01-29 2022-08-02 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途
CA3141826A1 (fr) * 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
CA3142351A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
GB202001856D0 (en) * 2020-02-11 2020-03-25 Inorbit Therapeutics Ab Compounds useful in inhibiting ketohexokinase and methods of making and using the same
MX2023001818A (es) 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
DE60333866D1 (de) * 2002-12-11 2010-09-30 Bayer Schering Pharma Ag 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
ATE481103T1 (de) 2003-04-09 2010-10-15 Wyeth Llc Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AU2006305538B2 (en) 2005-10-21 2012-06-28 Idorsia Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
US20100035863A1 (en) * 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
MX2009011089A (es) * 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
TW200911787A (en) * 2007-07-03 2009-03-16 Astrazeneca Ab New aza-bicyclohexane compounds useful as inhibitors of thrombin
EP2225253B1 (fr) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Dérivés d'acide phosphonique et leur utilisation en tant qu'antagonistes du récepteur p2y12
EP2238127B1 (fr) 2007-12-26 2012-08-15 Sanofi Dérivés de pyrazole-carboxamide utiles en tant qu'antagonistes de p2y12
EP2238128B1 (fr) 2007-12-26 2012-08-22 Sanofi Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
CA2756654C (fr) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Derives de thiazole et leur utilisation comme antagonistes des recepteurs p2y12

Also Published As

Publication number Publication date
CA2756542A1 (fr) 2010-10-14
SG175075A1 (en) 2011-11-28
CL2011002467A1 (es) 2012-02-24
IL215517A0 (en) 2011-12-29
CN102369197A (zh) 2012-03-07
EP2417128A2 (fr) 2012-02-15
US20120028989A1 (en) 2012-02-02
AU2010233378A1 (en) 2011-11-24
KR101694563B1 (ko) 2017-01-09
ZA201108158B (en) 2014-04-30
MX2011010200A (es) 2011-10-14
CA2756542C (fr) 2017-08-22
BRPI1014039A2 (pt) 2018-04-03
JP5536873B2 (ja) 2014-07-02
WO2010116328A3 (fr) 2011-01-13
RU2011144763A (ru) 2013-05-20
EP2417128B1 (fr) 2016-03-02
WO2010116328A2 (fr) 2010-10-14
CN102369197B (zh) 2013-11-06
ES2567311T3 (es) 2016-04-21
NZ596213A (en) 2013-05-31
JP2012523406A (ja) 2012-10-04
US8288385B2 (en) 2012-10-16
KR20120070627A (ko) 2012-06-29

Similar Documents

Publication Publication Date Title
MA33260B1 (fr) 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
MA32277B1 (fr) Derives de 2-phenyl-4- cyclopropyl-pyrimidine
MA30868B1 (fr) Derives de 2-aminocarbonyl-pyridine
MA33277B1 (fr) Dérivés de thiazole et leur utilisation comme antagonistes des récepteurs p2y12
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
MY165273A (en) Anti-cd48 antibodies and uses thereof
MA30903B1 (fr) Derives de 2 - phenyl-6-minocarbonyl-pyrimidine
TW200640877A (en) Pyrimidine derivatives
EA201291441A1 (ru) Пробиотические штаммы для применения при улучшении состояния кишечной нервной системы
MY153749A (en) Phosphonic acid derivates and their use as p2y12 receptor antagonists
UA102065C2 (xx) Заміщені 4-арил-1,4-дигідро-1,6-нафтиридинаміди і їх застосування$замещенные 4-арил-1,4-дигидро-1,6-нафтиридинамиды и их применение
EP2486060A4 (fr) Anticorps anti-siglec 15 dans le traitement de maladies liées à une perte osseuse
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EP2485751A4 (fr) Procédés de traitement de la dépression et d'autres maladies associées
EA201270480A1 (ru) Новые соединения
MA35458B1 (fr) Variants du facteur de croissance des fibroblastes 21
EA201390830A1 (ru) Соединения и их применение в качестве ингибиторов фермента расщепления бета-сайта app (bace)
WO2011141823A3 (fr) Méthodes de traitement et/ou de prévention de troubles de prolifération cellulaire à l'aide d'antagonistes de il-17
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
TN2009000529A1 (en) Methods and compositions for treating allergic diseases
TW200736275A (en) Methods and compositions for treating allergic diseases
MX2015002289A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso.
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
MA32282B1 (fr) Dérivés de 2-phényl-pyridine substitués